Evidence map›Paper›PMID 38594360›Full record

ArticleNPJ precision oncology2024

Development and validation of a deep learning-based microsatellite instability predictor from prostate cancer whole-slide images.

Qiyuan Hu, Abbas A Rizvi, Geoffery Schau, Kshitij Ingale, Yoni Muller, Rachel Baits, Sebastian Pretzer, Aïcha BenTaieb, Abigail Gordhamer, Roberto Nussenzveig and 7 more

Open access · goldAbstract read
In one paragraph

Article in NPJ precision oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
5.9field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 14 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Review
  9. Deficient Mismatch Repair and Microsatellite Instability in Solid Tumors.International journal of molecular sciences · 2025
    Review
  10. Review
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 2 institutions in 2 countries.

Qiyuan HuTempus AI, Inc, 600 W Chicago Ave #510, Chicago, IL, 60654, USA.ORCID http://orcid.org/0000-0002-3326-6441
Abbas A RizviTempus AI, Inc, 600 W Chicago Ave #510, Chicago, IL, 60654, USA.
Geoffery SchauTempus AI, Inc, 600 W Chicago Ave #510, Chicago, IL, 60654, USA.
Kshitij IngaleTempus AI, Inc, 600 W Chicago Ave #510, Chicago, IL, 60654, USA.ORCID http://orcid.org/0009-0001-5789-8443
Yoni MullerTempus AI, Inc, 600 W Chicago Ave #510, Chicago, IL, 60654, USA.
Rachel BaitsTempus AI, Inc, 600 W Chicago Ave #510, Chicago, IL, 60654, USA.ORCID http://orcid.org/0009-0003-1478-0757
Sebastian PretzerWork done while at Tempus AI, Inc, 600 W Chicago Ave #510, Chicago, IL, 60654, USA.
Aïcha BenTaiebWork done while at Tempus AI, Inc, 600 W Chicago Ave #510, Chicago, IL, 60654, USA.
Abigail GordhamerPathNet, Inc, 5100 Talley Rd Suite 300, Little Rock, AR, 72204, USA.
Roberto NussenzveigPathNet, Inc, 5100 Talley Rd Suite 300, Little Rock, AR, 72204, USA.ORCID http://orcid.org/0000-0003-2612-1348
Adam ColePathNet, Inc, 5100 Talley Rd Suite 300, Little Rock, AR, 72204, USA.
Matthew O LeavittPathNet, Inc, 5100 Talley Rd Suite 300, Little Rock, AR, 72204, USA.
Ryan D JonesTempus AI, Inc, 600 W Chicago Ave #510, Chicago, IL, 60654, USA.
Rohan P JoshiTempus AI, Inc, 600 W Chicago Ave #510, Chicago, IL, 60654, USA.
Nike BeaubierTempus AI, Inc, 600 W Chicago Ave #510, Chicago, IL, 60654, USA.ORCID http://orcid.org/0000-0002-5956-0198
Martin C StumpeTempus AI, Inc, 600 W Chicago Ave #510, Chicago, IL, 60654, USA.
Kunal NagpalTempus AI, Inc, 600 W Chicago Ave #510, Chicago, IL, 60654, USA. kunal.nagpal@tempus.com.
Tempus Labs (United States) · USAsha Foundation · IN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Microsatellite instability-high (MSI-H) is a tumor-agnostic biomarker for immune checkpoint inhibitor therapy. However, MSI status is not routinely tested in prostate cancer, in part due to low prevalence and assay cost. As such, prediction of MSI status from hematoxylin and eosin (H&E) stained whole-slide images (WSIs) could identify prostate cancer patients most likely to benefit from confirmatory testing to evaluate their eligibility for immunotherapy and need for Lynch syndrome testing. Prostate biopsies and surgical resections from prostate cancer patients referred to our institution were analyzed. MSI status was determined by next-generation sequencing. Patients sequenced before a cutoff date formed an algorithm development set (n = 4015, MSI-H 1.8%) and a paired validation set (n = 173, MSI-H 19.7%) that consisted of two serial sections from each sample, one stained and scanned internally and the other at an external site. Patients sequenced after the cutoff date formed a temporally independent validation set (n = 1350, MSI-H 2.3%). Attention-based multiple instance learning models were trained to predict MSI-H from H&E WSIs. The predictor achieved area under the receiver operating characteristic curve values of 0.78 (95% CI [0.69-0.86]), 0.72 (95% CI [0.63-0.81]), and 0.72 (95% CI [0.62-0.82]) on the internally prepared, externally prepared, and temporal validation sets, respectively, showing effective predictability and generalization to both external staining/scanning processes and temporally independent samples. While MSI-H status is significantly correlated with Gleason score, the model remained predictive within each Gleason score subgroup.

Identifiers

PMID38594360
PMCPMC11004110
OpenAlexW4394612852

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.